{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.0","upperLimit":"92.4","value":"87.2"},{"groupId":"OG001","lowerLimit":"76.8","upperLimit":"92.5","value":"84.6"},{"groupId":"OG002","lowerLimit":"50.0","upperLimit":"80.8","value":"65.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"40"}],"units":"Participants"}],"title":"EFS Eligible & evaluable patients without 1p loss"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.3","upperLimit":"100.0","value":"99.4"},{"groupId":"OG001","lowerLimit":"87.2","upperLimit":"98.4","value":"92.8"},{"groupId":"OG002","lowerLimit":"71.6","upperLimit":"95.8","value":"83.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"40"}],"units":"Participants"}],"title":"OS Eligible & evaluable patients without 1p loss"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"84.7","upperLimit":"100.0","value":"94.7"},{"groupId":"OG002","lowerLimit":"65.2","upperLimit":"98.4","value":"81.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"EFS Eligible & evaluable patients with 1p loss"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"84.7","upperLimit":"100.0","value":"94.7"},{"groupId":"OG002","lowerLimit":"86.5","upperLimit":"100.0","value":"95.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"OS Eligible & evaluable patients with 1p loss"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.0","upperLimit":"92.4","value":"87.2"},{"groupId":"OG001","lowerLimit":"80.7","upperLimit":"94.2","value":"87.5"},{"groupId":"OG002","lowerLimit":"59.5","upperLimit":"87.0","value":"73.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"43"}],"units":"Participants"}],"title":"EFS Eligible & evaluable patients with normal 11q"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.3","upperLimit":"100.0","value":"99.4"},{"groupId":"OG001","lowerLimit":"88.7","upperLimit":"98.7","value":"93.7"},{"groupId":"OG002","lowerLimit":"77.4","upperLimit":"98.1","value":"87.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"43"}],"units":"Participants"}],"title":"OS Eligible & evaluable patients with normal 11q"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"45.0","upperLimit":"100.0","value":"75.0"},{"groupId":"OG002","lowerLimit":"42.7","upperLimit":"88.2","value":"65.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"title":"EFS Eligible & evaluable patients w/unbalanced 11q"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"64.6","upperLimit":"100.0","value":"87.5"},{"groupId":"OG002","lowerLimit":"72.9","upperLimit":"100.0","value":"88.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"title":"OS Eligible & evaluable patients w/unbalanced 11q"}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"62"}],"units":"Participants"}],"description":"Addressed by a descriptive comparison of the EFS and OS rates for patients with 1p loss vs without 1p loss, and for those with unbalanced 11q vs normal 11q.","dispersionType":"95% Confidence Interval","groups":[{"description":"2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.","id":"OG000","title":"Group 2 (Chemotherapy, Surgery)"},{"description":"4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.","id":"OG001","title":"Group 3 (Chemotherapy, Surgery)"},{"description":"8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients \\< 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.","id":"OG002","title":"Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)"}],"paramType":"NUMBER","populationDescription":"Eligible intermediate risk patients with 1p and 11q data.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Definitive Determination of the Prognostic Ability of 1p and 11q","type":"PRIMARY","unitOfMeasure":"percentage of 3 yr EFS/OS rate"}